Population
Patients undergoing dialysis therapy (hemodialysis and peritoneal dialysis) with hypertension
Design
Review
Authors
Loading...
BP variability assessment may refine CV risk stratification in dialysis; leaves open whether it changes management or outcomes.
Highlights the importance of volume control and individualized pharmacological therapy for hypertension in dialysis patients, while noting the critical need for high-quality clinical trials.
Yoshihiro Taniyama (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: